In an expert review, the authors provide transparency about biosimilar production, approvals, risk, and benefits to help improve confidence that the same safety and efficacy can be expected from biologics and their biosimilars.
Despite their size, complexity, and heterogeneity, biopharmaceuticals and their biosimilars can be expected to be safe and effective irrespective of batch or production history, according to a recent review in Expert Opinion on Biological Therapy, published online January 10, 2018, by William C. Lamanna, PhD, and colleagues.
The researchers, all employees and shareholders of Sandoz/Novartis, conclude that modern analytic methods, manufacturing quality systems, and comparability requirements for the evaluation of manufacturing changes help to ensure the consistent quality and clinical performance of biologics throughout their product lifecycles. More than a decade of real-world experience with biosimilars in Europe and the demonstrated success and safety of biosimilars have not done away with skepticism—particularly in the United States—about product regulation and quality. In this expert review, the authors provide transparency about biosimilar production, approvals, risk, and benefits to help improve confidence that the same safety and efficacy can be expected from biologics and their biosimilars.
Biologic therapies have a demonstrably long track record of consistent safety and effectiveness over the entire course of their often decades-long lifecycles. There have been only rare historical instances where clinically relevant changes have occurred—a situation defined as “clinical drift.” The review analyzes these cases and discusses modern tools in place to prevent them, including improved analytics, quality systems, and regulatory frameworks. Variability resulting in clinical differences is extremely rare, with only a single verifiable case resulting in adverse events in over 35 years and over 260 products, the reviewers note.
Despite this history, as the number of biosimilars increase, concerns regarding the ability of biosimilars to maintain equivalent clinical performance with their reference products have been disseminated. At the center of these concerns is the misconception that the sheer complexity and heterogeneity of biologic products precludes effective monitoring and control of relevant quality attributes. But, the reviewers point out, biosimilars employ the same post-approval regulatory framework and quality systems as their respective originator products to maintain quality and clinical performance. “Effective strategies for maintaining product quality and clinical performance are a pivotal regulatory requirement for the production of biopharmaceuticals, including biosimilars,” the review states.
To this end, production quality systems based around the central concepts of Good Manufacturing Practices (GMP) and the Pharmaceutical Quality System (PQS) have been developed to help ensure consistent production of safe and efficacious products over time and worldwide, irrespective of manufacturing process changes.
GMP was established in the 1990s to set up international requirements for a huge array of quality control measures, ranging from personnel and equipment to laboratory controls. In addition to GMP, the Pharmaceutical Quality System (PQS) was established, which has as its core objectives consistently achieving a realization of safe and effective medicines, establishing and maintaining product control, and continually improving products and processes to mitigate quality risks. Analytical capabilities and modern quality systems are always evolving to ensure consistent biopharmaceutical quality.
The review discusses recent improvements in manufacturing quality systems including:
Finally, quality systems must be continually evaluated and improved for robust maintenance of product quality, and to improve confidence in the safety and efficacy of reference biologics and their biosimilar products.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.